Health
Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics
Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced a landmark fulfillment agreement with MWI Animal Health (MWI), part of global healthcare company Cencora, to create the first-ever ultra-low temperature cold chain for veterinary medicine. This comes as Gallant advances toward delivering the potential first-ever FDA-approved off-the-shelf veterinary stem cell therapy, pending conditional approval by the U.S. Food and Drug Admini
About this update from Cencora, Inc.
[{"type":"text","content":"Agreement establishes first ultra-low temperature cold chain in veterinary medicine ahead of anticipated potential first FDA-approved, off-the-shelf stem cell therapy","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced a landmark fulfillment agreement with MWI Animal Health (MWI), part of global healthcare company Cencora, to create the first-ever ultra-low temperature cold chain for veterinary medicine. This comes as Gallant advances toward delivering the potential first-ever FDA-approved off-the-shelf veterinary stem cell therapy, pending conditional approval by the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM).","length":596,"tagName":"p"},{"type":"text","content":"Together, the companies are laying the foundation for a new category of veterinary care.","length":88,"tagName":"p"},{"type":"text","content":"The first expected product from Gallant's pipeline is sonruvetcel injectable suspension—a potential first-in-class, uterine-derived allogeneic mesenchymal stromal cell (MSC) therapy for cats with refractory feline chronic gingivostomatitis (rFCGS). Partnership with MWI will enable reliable delivery of veterinary stem cell therapies requiring storage at -80°C.","length":365,"tagName":"p"},{"type":"text","content":""Breakthrough science only matters if we can safely and reliably put it into the hands of veterinary professionals," said Dr. Linda Black, DVM, Ph.D., CEO of Gallant. "With MWI, we are pairing regenerative medicine innovation with world class supply chain management. This partnership helps ensure that, once approved, veterinarians can conveniently access an FDA-regulated, off-the-shelf stem cell therapy with confidence in its quality and integrity."","length":473,"tagName":"p"},{"type":"text","content":""This partnership demonstrates how distribution innovation can unlock clinical innovation," said Julia Loew, CCO at MWI Animal Health. "Stem cell therapies require precision handling. By investing in ultra-low temperature logistics tailored to veterinary practice, we are ensuring that this category of innovation can be delivered to clinics in the exact state intended, read...